Utilization of gabapentin by people in treatment for substance use disorders in Belgium (2011–2014): a cross-sectional study
Abstract Background Although gabapentin has been licensed in the European Union only for neuropathic pain and epilepsy for patients who have partial seizures, it has also been prescribed in treatment for substance use disorders. Many studies report the potential risk of abuse of gabapentin by people...
Main Authors: | Luk Van Baelen, Karin De Ridder, Jérôme Antoine, Lies Gremeaux |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-03-01
|
Series: | Archives of Public Health |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13690-018-0254-8 |
Similar Items
-
Longitudinal pharmacoepidemiological and health services research for substance users in treatment: protocol of the Belgian TDI-IMA linkage
by: Luk Van Baelen, et al.
Published: (2018-01-01) -
Use of health care services by people with substance use disorders in Belgium: a register-based cohort study
by: Luk Van Baelen, et al.
Published: (2021-06-01) -
Prevalence of HCV among people who inject drugs in Brussels—a respondent-driven sampling survey
by: Luk Van Baelen, et al.
Published: (2020-02-01) -
Comparative Effectiveness and Safety of Original Gabapentin and Generic Gabapentin in Treating Patients with Neuropathic Pain at Siriraj Hospital, Bangkok, Thailand
by: Rungsan Chaisewikul, et al.
Published: (2020-07-01) -
Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review
by: Saeed Ahmed, et al.
Published: (2019-05-01)